Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

PRESS RELEASE : CEVEC Pharmaceuticals GmbH: CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies

07/27/2021 | 08:01am EDT
DGAP-News: CEVEC Pharmaceuticals GmbH / Key word(s): Financing 
CEVEC Pharmaceuticals GmbH: CEVEC closes growth financing round to serve strong demand in viral vector technologies for 
cell and gene therapies 
2021-07-27 / 14:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies 
  . With its highly scalable Adenovirus and AAV production technologies, CEVEC provides cutting-edge manufacturing 
    solutions for two of the most widely used gene therapy vectors 
  . Funding will expand cell line development capacities for ELEVECTA(R) stable AAV producer cell lines 
  . With ELEVECTA(R) currently being implemented in a second host cell type, an even stronger demand is expected 
Cologne, Germany, July 27^th, 2021 
CEVEC Pharmaceuticals GmbH (CEVEC), the leading provider of high-performance cell technology for scalable manufacturing 
of advanced bio-therapeutics, today announced the successful closing of an internal growth financing round. Being 
profitable in 2020, the company plans to use the funds to accelerate company growth and to further build up cell line 
development capacities to address the growing market in viral vector production. CEVEC also announced that the ELEVECTA 
(R) Technology is currently being implemented in HEK293 as a second host cell type. As HEK293 is the most widely used 
host cell line in gene therapy manufacturing, CEVEC expects to see a significant increase in demand from clients and 
partners. 
"CEVEC is in a very important stage of development. As pharma companies are increasingly building up their gene therapy 
portfolios, this is the right time to invest and expand the company's cell line development capacities in order to 
address the growing market for our technologies," said Dr. Nicole Faust, Chief Executive Officer at CEVEC. "We are 
delighted to experience the strong support of our investors in this capacity expansion program. We want to take the 
opportunity to thank them for their commitment, realizing we share the same vision - turning CEVEC's technologies into 
the gold standard for viral vector manufacturing." 
"Gene therapies are often the only treatment option for many severe and life-threatening diseases, and they have 
evolved as one of the main growth drivers in pharma and biotech. Therefore, the potential for novel production 
technologies as offered by CEVEC is enormous," said Aristotelis Nastos, Head of Life Sciences & Cleantech at NRW.Bank. 
"We are delighted to be part of this financing round with the aim of accelerating the company's growth and becoming 
market leader for stable vector manufacturing technologies in cell and gene therapies." 
CEVEC provides superior solutions for vector manufacturing 
The use of viral vectors in cell and gene therapy is vital. The challenge for the pharmaceutical industry now is to 
establish production processes that can keep up with the increasing demand for volume and consistent quality. With its 
highly scalable production cell lines for vectors based on Adeno-Associated Virus (AAV) and Adenovirus, CEVEC covers 
two of the most widely used viral vectors for delivering therapeutic genes to target cells and tissues. The proprietary 
technologies are characterized by unique advantages in the industry: CEVEC's ELEVECTA(R) Technology for stable AAV 
production is a revolutionary approach to AAV manufacturing, as the producer cells have all the necessary components 
stably integrated into the genome, making production processes similar to monoclonal antibody production. The CAP(R) 
Technology is best suited for the production of Adenoviral vectors, as it is specifically designed to avoid the 
production of Replication-Competent Adenovirus (RCA). 
About CEVEC: 
CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics from 
R&D to manufacturing scale. The company's product portfolio comprises platform technologies for gene therapy viral 
vectors, vaccines and complex recombinant proteins. With the ELEVECTA(R) Technology, CEVEC offers a unique solution for 
large-scale production of AAV vectors using helper virus-free producer cell lines with all necessary components stably 
integrated into the cell. The technology is based on suspension cells and does not require any expensive transfection 
reagents and cGMP plasmids. CEVEC's CAP(R) Technology based on human suspension cells is the ideal production platform 
for RCA-free Adenoviral vectors, Lentiviral vectors, viral vaccines and exosomes. With the CAP-Go(R) Technology CEVEC 
provides a solution to the increasing need for recombinant production of complex and highly glycosylated protein 
molecules, including laminins, coagulation factors and plasma proteins. 
About the gene therapy market: 
The global gene therapy market size was valued at approximately USD 2.3 billion in 2020 and is expected to grow at a 
CAGR of 20.4% from 2021 to 2028.^[1] With twenty cell and gene therapy products already approved, and over four hundred 
human gene therapy clinical trials being conducted globally, there is enormous potential for the treatment of rare 
inherited and other devastating diseases. Moreover, gene therapies are in development for diseases like Alzheimer's or 
Parkinson's with large numbers of patients, which is expected to lead to a high demand for viral vector manufacturing 
capacity. 
For more information, please visit the Company's website. 
Follow CEVEC on LinkedIn and Twitter. 
Contact: 
CEVEC Pharmaceuticals GmbH MC Services AG 
Dr. Nicole Faust           Dr. Solveigh Mähler 
CEO                        Public Relations 
P.: +49 221 460 208 00     P.: +49 211 529 252 19 
E.: info@cevec.com         E.: solveigh.maehler@mc-services.eu 

^[1] Grand View Research (GVR), Gene Therapy Market Size, Share & Trends Analysis (02/2021), Report ID: GVR-2-68038-179-5 -----------------------------------------------------------------------------------------------------------------------

2021-07-27 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------

1221756 2021-07-27

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1221756&application_name=news 
 

(END) Dow Jones Newswires

July 27, 2021 08:00 ET (12:00 GMT)

Latest news "Companies"
05:59pKRATON CORPORATION ALERT : Bragar Eagel & Squire, P.C. Investigates Sale of KRA and Encourages Investors to Contact the Firm
GL
05:59pKRATON CORPORATION ALERT : Bragar Eagel & Squire, P.C. Investigates Sale of KRA and Encourages Investors to Contact the Firm
GL
05:58pNVENT ELECTRIC : Announces Quarterly Cash Dividend
BU
05:55pRefinitiv agrees to pay a civil penalty of $650,000 for failing to report certain swap data -CFTC
RE
05:54pU.S. environment agency urged by 21 states to toughen vehicle emissions rewrite
RE
05:52pGENERAL ANNOUNCEMENT : :ienova reports about the transaction announced by its controlling shareholder
PU
05:52pOctober 15 Deadline Approaches for Advance Child Tax Credit
PU
05:52pMERCURY NZ : Commerce Commission grants clearance for Mercury to acquire Trustpower's retail business
PU
05:52pSANDERSON FARMS : Donates $1 Million to American Red Cross Hurricane Ida Relief Efforts
PU
05:52pGENERAL MILLS : Quarterly Dividend Declared
BU
Latest news "Companies"